/MIST
MIST Stock - Milestone Pharmaceuticals Inc.
Healthcare|BiotechnologyNASDAQ
$2.15+3.37%
+$0.07 (+3.37%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.77
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+272.1%upside
Target: $8.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MIST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.13 – $2.17
TARGET (TP)$8.00
STOP LOSS$1.98
RISK/REWARD1:34.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.41
52W High$3.06
52W Low$0.63
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $1.00M | $5.00M | $15.00M | N/A |
| Gross Profit | N/A | $1.00M | $5.00M | $15.00M | N/A |
| Gross Margin | N/A | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-42,102,000 | $-61,098,000 | $-59,642,000 | $-43,073,000 | $-50,710,000 |
| Net Income | $-41,519,000 | $-59,685,000 | $-58,388,000 | $-42,853,000 | $-49,967,000 |
| Net Margin | N/A | -5968.5% | -1167.8% | -285.7% | N/A |
| EPS | $-0.67 | $-1.39 | $-1.35 | $-1.02 | $-1.70 |
Company Overview
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$7
Average Target
↑ 210.1% Upside
Now
$4
Low
$7
Average
$10
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | TD Cowen | Upgrade | Buy | $8 |
| September 11th 2025 | Wells Fargo | Initiation | Overweight | $4 |
| June 5th 2025 | H.C. Wainwright | Resumed | Buy | $5 |
| August 22nd 2024 | Rodman & Renshaw | Initiation | Buy | $9 |
| June 20th 2023 | Jefferies | Downgrade | Hold | $4← $8 |
| April 22nd 2022 | Piper Sandler | Upgrade | Overweight | $10← $8 |
Earnings History & Surprises
MISTBeat Rate
67%
Last 18 quarters
Avg Surprise
+8.0%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.12
Q4 2025
EPS Surprise History
Q1 24
-6.7%
$-0.32vs$-0.30
Q2 24
+19.2%
$-0.21vs$-0.26
Q3 24
+26.3%
$-0.14vs$-0.19
Q4 24
+12.5%
$-0.14vs$-0.16
Q1 25
-26.7%
$-0.19vs$-0.15
Q2 25
-63.2%
$-0.31vs$-0.19
Q3 25
-11.1%
$-0.20vs$-0.18
Q4 25
+29.4%
$-0.12vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.18 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.17 | $-0.12 | +29.4% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.18 | $-0.20 | -11.1% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.19 | $-0.31 | -63.2% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.15 | $-0.19 | -26.7% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.16 | $-0.14 | +12.5% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.19 | $-0.14 | +26.3% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.26 | $-0.21 | +19.2% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.30 | $-0.32 | -6.7% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.38 | $-0.35 | +7.9% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.39 | $-0.37 | +5.1% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.38 | $-0.35 | +7.9% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | $-0.35 | $-0.31 | +11.4% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.41 | $-0.34 | +17.1% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.36 | $-0.39 | -8.3% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.39 | $-0.33 | +15.4% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-0.36 | $-0.40 | -11.1% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.38 | $-0.34 | +10.5% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.26 | $0.02 | +107.7% | ✓ BEAT |
Latest News
Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Raises Price Target to $8
📈 PositiveBenzinga•Dec 16, 2025, 03:02 PM
TD Cowen Upgrades Milestone Pharmaceuticals to Buy, Announces $8 Price Target
📈 PositiveBenzinga•Dec 15, 2025, 04:34 PM
HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Raises Price Target to $8
📈 PositiveBenzinga•Dec 15, 2025, 03:56 PM
Market-Moving News for December 15th
➖ NeutralBenzinga•Dec 15, 2025, 12:26 PM•Also:
Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 15, 2025, 12:00 PM
Reported Friday, Milestone Wins FDA Approval For CARDAMYST, First Self-Administered Nasal Spray For Paroxysmal Supraventricular Tachycardia
📈 PositiveBenzinga•Dec 15, 2025, 08:05 AM
Trading Halt: Halted at 6:06:34 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 12, 2025, 11:06 PM
Milestone Pharmaceuticals Q3 EPS $(0.12) Beats $(0.16) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 12:03 PM
Milestone Pharma Says New Data Analyses Of Investigational Product For PSVT, Etripamil Nasal Spray, Consistently Showed Efficacy And Favorable Safety Profile Across Multiple Studies Comprising Global Development Program
📈 PositiveBenzinga•Nov 3, 2025, 01:11 PM
Wells Fargo Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $4
📈 PositiveBenzinga•Sep 11, 2025, 11:57 AM
Milestone Pharmaceuticals plunges after pricing $52.5M offering
📉 NegativeSeeking Alpha•Jul 11, 2025, 02:41 PM
Milestone Pharmaceuticals proposes capital raise via securities offering
➖ NeutralSeeking Alpha•Jul 11, 2025, 10:34 AM
Frequently Asked Questions about MIST
What is MIST's current stock price?
Milestone Pharmaceuticals Inc. (MIST) is currently trading at $2.15 per share. The stock has moved +3.37% today.
What is the analyst price target for MIST?
The average analyst price target for MIST is $8.00, based on 1 analyst.
What sector is Milestone Pharmaceuticals Inc. in?
Milestone Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MIST's market cap?
Milestone Pharmaceuticals Inc. has a market capitalization of $0.18 billion, making it a small-cap company.
Does MIST pay dividends?
No, Milestone Pharmaceuticals Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPLT
Applied Therapeutics, Inc.
$0.13
Mkt Cap: $0.0B
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$8.12
Mkt Cap: $0.1B
CRDF
Cardiff Oncology, Inc.
$2.57
Mkt Cap: $0.2B
CYBN
Cybin Inc.
$7.18
Mkt Cap: $0.4B
ELTX
Elicio Therapeutics, Inc.
$7.94
Mkt Cap: $0.1B
IPHA
Innate Pharma S.A.
$1.75
Mkt Cap: $0.1B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
RANI
Rani Therapeutics Holdings, Inc.
$1.51
Mkt Cap: $0.1B
SAVA
Cassava Sciences, Inc.
$2.17
Mkt Cap: $0.1B
Explore stocks similar to MIST for comparison